Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study

Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study

<i>Background and Objectives:</i> Small-cell lung cancer (SCLC) is an exceedingly aggressive neoplasm distinguished by an unfavorable prognosis. Recent studies have confirmed chemo-immunotherapy as the conventional first treatment for extensive-stage small-cell lung cancer (ES-SCLC), but...

Full description

Saved in:
Bibliographic Details
Main Authors: Mehmet Nuri Baser, Bilgin Demir, Gamze Serin Ozel, Gamze Gokoz Dogu, Serdar Karakaya, Mucahit Ugar, Naziye Ak, Ahmet Ozveren, Ufuk Camanlı, Olcun Umit Unal, Merve Turan, Esin Oktay
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Medicina
Subjects:
immunotherapy
chemotherapy
small-cell lung cancer
Online Access:https://www.mdpi.com/1648-9144/61/7/1230
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items